The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Практическое руководство Европейской ассоциации сердечного ритма 2018 года по применению пероральных антикоагулянтов, не являющихся антагонистами витамина K, у пациентов с фибрилляцией предсердий
Gregory Y.H. Lip, Tatjana Potpara, Laurent Fauchier, A. John Camm, Hein Heidbüchel, Peter B. Verhamme, Matthias Antz, Jonas Oldgren, Peter Sinnaeve, Wataru Shimizu, Jan Steffel, Jeffrey Ian Weitz, Giuseppe Boriani, ESC Scientific Document Group, Andreas Goette, Roberto O. Keegan, Deirdre A. Lane, Karl Georg Hæusler, Chern‐En Chiang, Robert J. MacFadyen, Boyoung Joung, Vanessa Roldán, Rónán Collins, Holger Reinecke, Pierre Albaladejo, Lien Desteghe, Nigel Rowell
2018-03-01

anticoagulant managementatrial fibrillationdrug-drug interactionsnon-vitamin K antagonist oral anticoagulantsstroke prevention
The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651; Heidbuchel et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the use of these drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. The European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group identified 20 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. The 20 topics are as follows i.e., (1) Eligibility for NOACs; (2) Practical start-up and follow-up scheme for patients on NOACs; (3) Ensuring adherence to prescribed oral anticoagulant intake; (4) Switching between anticoagulant regimens; (5) Pharmacokinetics and drug-drug interactions of NOACs; (6) NOACs in patients with chronic kidney or advanced liver disease; (7) How to measure the anticoagulant effect of NOACs; (8) NOAC plasma level measurement: rare indications, precautions, and potential pitfalls; (9) How to deal with dosing errors; (10) What to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a potential risk of bleeding; (11) Management of bleeding under NOAC therapy; (12) Patients undergoing a planned invasive procedure, surgery or ablation; (13) Patients requiring an urgent surgical intervention; (14) Patients with AF and coronary artery disease; (15) Avoiding confusion with NOAC dosing across indications; (16) Cardioversion in a NOAC-treated patient; (17) AF patients presenting with acute stroke while on NOACs; (18) NOACs in special situations; (19) Anticoagulation in AF patients with a malignancy; and (20) Optimizing dose adjustments of VKA. Additional information and downloads of the text and anticoagulation cards in different languages can be found on an EHRA website (www.NOACforAF.eu).
1
Covered topics include treatment eligibility, initiation and follow-up, adherence, switching therapies, pharmacokinetics, drug interactions, organ disease, anticoagulant measurement, dosing errors, overdose, and bleeding management.
2
NOACs are presented as an alternative to vitamin K antagonists for stroke prevention and have become the preferred choice, especially when anticoagulation is newly initiated.
3
The 2018 document is the second update of EHRA’s Practical Guide for using non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
4
The guide addresses unresolved practical questions about NOAC use through evidence-based recommendations for 20 concrete clinical scenarios.

Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation

Practical clinical use, including eligibility, dosing, monitoring, adherence, interactions, and management of complications

Publication Details
Publication Date
2018-03-01
Journal
Publisher
ISSN
Cited by
2123
Access Type
Author Information
Authors
Gregory Y.H. Lip
Tatjana Potpara
Laurent Fauchier
A. John Camm
Hein Heidbüchel
Peter B. Verhamme
Matthias Antz
Jonas Oldgren
Peter Sinnaeve
Wataru Shimizu
Jan Steffel
Jeffrey Ian Weitz
Giuseppe Boriani
ESC Scientific Document Group
Andreas Goette
Roberto O. Keegan
Deirdre A. Lane
Karl Georg Hæusler
Chern‐En Chiang
Robert J. MacFadyen
Boyoung Joung
Vanessa Roldán
Rónán Collins
Holger Reinecke
Pierre Albaladejo
Lien Desteghe
Nigel Rowell
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%